• HyperMed’s solution uses patented technologies for assessing oximetry in superficial tissue

  • Physicians are able to determine quantitative measurements for oxyhemoglobin and deoxyhemoglobin levels in superficial tissue

The Solution

HyperMed’s technology utilizes a proprietary form of hyperspectral imaging to assess oximetry in superficial tissue. It does not require contact with the patient and does not require injectable contrast. It uses visible light and a spectrometer to image and quantify light absorption in hemoglobin molecules.


HyperMed’s hyperspectral imaging technology is designed to differentiate light absorption between oxygenated hemoglobin and deoxygenated hemoglobin.

The technology presents the data as color-coded images depicting approximate concentrations of oxyhemoglobin and deoxyhemoglobin, as well as oxygen saturation. Software tools allow the clinician to analyze various areas within the image corresponding to locations on the skin surface. Such is useful to determine the location of ischemic tissue.

HyperMed’s new tissue oximetry device called HyperView™ is FDA 510(k) cleared.
HyperMed, HyperView, OxyVu™-1 and the company logo are trademarks of HyperMed Imaging, Inc.